<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "cytarabine liposome inj VIAL">
<dose><value>50</value>
</dose><route><value>INTRATHECAL</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>cytarabine liposome inj VIAL</value>
</drugname><strength><value>10 mg/mL</value>
</strength><frequency><value>EVERY 14 DAYS</value>
<value>ONCE</value>
<value>EVERY 28 DAYS</value>
</frequency><instruction><value>for 2 doses.</value>
<value>Administer at week 5.</value>
<value>Administer at week 7.</value>
<value>Administer at week 9.</value>
<value>Administer at week 13.</value>
<value>for 4 doses.</value>
</instruction><volume><value>5 mL</value>
</volume><units><value>mg</value>
</units><additionalnotes><value>Solid Tunor Neoplastic Meningitis: Induction</value>
<value>Solid Tunor Neoplastic Meningitis: Consolidation. Administer at week 5, 7, 9, and 13 for a total of 4 doses.</value>
<value>Lymphomatous meningitis: Induction</value>
<value>Lymphomatous meningitis: Consolidation. Administer at week 5, 7, 9, and 13 for a total of 4 doses.</value>
<value>Lymphomatous meningitis: Maintenance</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3469</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary, Health Canada Special Access Programme.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>57665-331-01</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>